InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.00%
)
Bitcoin
61,889.60
(
-0.30%
)
Post# of 253281
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 61
Posts 11586
Boards Moderated 0
Alias Born 07/16/2006

jbog

Re: None

Monday, 12/21/2009 7:32:29 AM

Monday, December 21, 2009 7:32:29 AM

Post# of 253281
Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies

Lilly Gains Worldwide Rights for Incyte's Novel JAK1/JAK2 Inhibitor, INCB28050, for Inflammatory and Autoimmune Diseases
Incyte to Receive $90 Million Upfront Payment and up to $665 Million in Potential Milestones, Plus Royalties on Future Sales; Incyte Retains Co-Development & Co-Promotion Options
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up